A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Status:

Closed to Accrual

III

Phase

2nd+

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

HDR, BRCA1/2

Investigational

Product

Niraparib

PARP inhibitor (p.o.)

Treatment Arms

o Experimental: Niraparib

o Placebo Comparator: Placebo